Although an ASCO 2007 update of recommendations for the use of tumor markers in breast cancer concluded that available data were insufficient to support using ER status of DCIS in making decisions about tamoxifen treatment, we believe it is time to revise this recommendation to allow all patients with DCIS to have ER and PgR measured for a tailored treatment approach, a separate article published in the same issue stated tamoxifen and depression